Phase 2 Start~month

Phase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate Efficacy, Sa

Indication
Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Other upcoming events for ALNY

Phase 2 StartPhase 2 Start: HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharm
Phase 3 ReadoutPhase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Trans
Phase 3 ReadoutPhase 3 Topline: ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficac
Phase 3 ReadoutPhase 3 Topline: TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nu

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate Efficacy, Sa — ALNY Phase 2 Start | BioSniper